Here we determined that expression of miR-145, another potential tumor suppressor in neuroblastoma, was significantly lower in high-risk MYCN amplified tumors and that lower miR-145 expression was associated with worse EFS and OS in our patient cohort. This evidence concerns the gene MYCN and neuroblastoma.